Dilodin

Print
Barcode: 8935206094152
Description

DilodinDHG

COMPOSITION:

Diosmin ........................... 450 mg

Hesperidin ......................... 50 mg

Excipients q.s................... 1 tablet

(Wheat starch, avicel, PVP, magnesium stearate, HPMC, PVA, PEG 6000, talc, titanium dioxide, red ferric oxide, yellow ferric oxide).

DOSAGE FORM: Film coated tablet.

PRESENTATION: Box of 5 blisters x 10 tablets.          Box of 10 blisters x 10 tablets.

ACTIONS: The main component of DilodinDHG is a micronized purified flavonoid fraction (diosmin, hesperidin) which is a vascular protecting agent. The drug develops its actions by inhibiting hyaluronidase, an enzyme producing capillary hyperpermeability. In case this enzyme is redundant, a hypodermic hemorrhage state occurs.

DilodinDHG acts on reducing varicose veins and venous stasis, normalizing capillary permeability and strengthening capillary resistance. DilodinDHG is used in the treatment of venous dysfunction, especially in haemorrhoids with the internal medicine method.

INDICATIONS: Treatment of the symptoms of acute haemorrhoidal attacks and chronic haemorrhoidal disease.

Treatment of the symptoms associated with venolymphatic circulatory failure e.g., footsore, heavy legs, swelling in the legs, varicose veins, post-phlebitis, cramps.

CONTRAINDICATIONS: Hypersensitivity to any components of the drug. Pregnant women and breast-feeding mothers.

PRECAUTIONS: No documents have been reported.

PREGNANCY AND LACTATION: Animal studies have shown no teratogenicity; no harmful effect has so far been reported. No data recording the drug crosses breast milk. The drug should not be used in pregnant women and breastfeeding mothers.

EFFECTS ON ABILITY TO DRIVE AND USE MACHINES:

The drug does not affect the ability to drive and operate machinery.

INTERACTIONS: No documents have been reported.

ADVERSE EFFECTS: Gastrointestinal disturbances. Mild neurovegetative disorders have been rarely reported.

Inform your physician about any adverse effects occur during the treatment.

OVERDOSAGE: No documents have been reported.

DOSAGE & ADMINISTRATION: The oral doses are divided into 2 times, in lunch and dinner.

Acute haemorrhoidal attacks: 6 tablets daily for 4 days, then 4 tablets daily for 3 days, 2 tablets daily thereafter.

Chronic hemorrhoidal disease: 2 tablets daily.

Venous insufficiency (footsore, heavy legs, swelling in the legs, varicose veins, post-phlebitis, cramps): 2 tablets daily.

Or as directed by the physician.

Read the directions carefully before use.

Consult the physician for more information.

Shelf-life: 36 months from the manufacturing date.

Storage conditions: Store in dry places, not exceeding 30oC, protect from light.

Specifications: Manufacturer's.

Reviews

There are yet no reviews for this product.